NUCLEOLIN and breast carcinoma: Hence, in patients in which NCL overexpression activates ErbB2, the increased risk of breast cancer and the reduced survival are observed, whereas specific inhibition of NCL expression by GroA (AS1411) or shRNA transfection prevents NCL/ErbB2 interaction activating oncogenic pathways in ErbB2-positive breast cancer cells, thereby reduces oncogenic transformation and limits tumor growth and disease progression (Wolfson et al. 2016, 2018).